Present data suggests that both TLR4 and MyD88 have been involved in the progression of multiple cancers, but they also demonstrate a protective role when stimulated or inhibited depending on the cancer type or stage; thus, two TLR4 ligands have already been approved for cancer treatment [17]. The gene discussed is TLR4; the disease is cancer.